Dysregulation of long noncoding RNA MEG3 and NLRC5 expressions in patients with relapsing-remitting multiple sclerosis: is there any correlation?
Shahram TorkamandiShima BahramiTahereh GhorashiMohammad DehaniHadi BayatSeyyed Mohamad HoseiniSomaye RezaeiMohsen SoosanabadiPublished in: Genes and immunity (2021)
Long noncoding RNA MEG3 and NLRC5 genes are both involved in the immune system and the regulation of NLRC5 by MEG3 is documented in rheumatoid arthritis. Therefore, we intended to evaluate the association between the expressions of MEG3 and NLRC5 in multiple sclerosis (MS). Forty relapsing and remitting MS (RRMS) patients (20 in each group) and twenty healthy individuals were enrolled. The expression level of MEG3 and NLRC5 was assessed in peripheral blood mononuclear cells. Sub-group analysis demonstrated that the expression level of MEG3 is reduced in the relapse patient group compared to remission and healthy groups (p < 0.001). The expression level of NLRC5 was higher in whole patients compared with healthy controls (p < 0.05). Moreover, a negative correlation was observed between the expression of these two genes (r = -0.73, p < 0.0001). To conclude, our findings showed the dysregulation of MEG3 and NLRC5 expressions in RRMS patients. Also, the converse association of MEG3 and NLRC5 reflects that the role of MEG3 in MS development is probably mediated by modulation of NLRC5.
Keyphrases
- multiple sclerosis
- long noncoding rna
- end stage renal disease
- poor prognosis
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- resting state
- chronic kidney disease
- white matter
- disease activity
- prognostic factors
- mass spectrometry
- peritoneal dialysis
- functional connectivity
- ms ms
- dna methylation
- patient reported outcomes
- binding protein
- case report
- systemic sclerosis
- transcription factor
- idiopathic pulmonary fibrosis
- interstitial lung disease
- free survival